

## **TABLE OF CONTENTS**

<b>TITLE PAGE</b>	<b>i</b>
<b>APPROVAL PAGE</b>	<b>ii</b>
<b>AUTHENTICITY STATEMENT</b>	<b>iii</b>
<b>PREFACE</b>	<b>iv</b>
<b>TABLE OF CONTENTS</b>	<b>vi</b>
<b>LIST OF TABLES</b>	<b>viii</b>
<b>LIST OF FIGURES</b>	<b>ix</b>
<b>LIST OF APPENDICES</b>	<b>x</b>
<b>LIST OF ABBREVIATIONS</b>	<b>xi</b>
<b>ABSTRACT</b>	<b>xii</b>
<b>CHAPTER I INTRODUCTION</b>	<b>1</b>
<b>1.1. Background</b>	<b>1</b>
<b>1.2. Problem Formulation</b>	<b>3</b>
<b>1.3. Study Objective</b>	<b>3</b>
<b>1.4. Study Benefit</b>	<b>4</b>
<b>1.5. Study Originality</b>	<b>5</b>
<b>CHAPTER II LITERATURE REVIEW</b>	<b>8</b>
<b>2.1. Literature Review</b>	<b>8</b>
<b>2.2. Basic Theory</b>	<b>16</b>
<b>2.3. Theoretical Framework</b>	<b>17</b>
<b>2.4. Conceptual Framework</b>	<b>18</b>
<b>2.5. Hypothesis</b>	<b>18</b>

<b>CHAPTER III STUDY METHODOLOGY</b>	<b>19</b>
<b>3.1. Study Design</b>	<b>19</b>
<b>3.2. Study Settings</b>	<b>19</b>
<b>3.3. Study Subject and Population</b>	<b>19</b>
<b>3.4. Sample Size</b>	<b>20</b>
<b>3.5. Sampling Method</b>	<b>20</b>
<b>3.6. Inclusion and Exclusion Criteria</b>	<b>20</b>
<b>3.7. Drop Out Criteria</b>	<b>21</b>
<b>3.8. Study Variables</b>	<b>21</b>
<b>3.9. Operational Definition of Variables</b>	<b>21</b>
<b>3.10. Study Materials and Tools</b>	<b>22</b>
<b>3.11. Study Procedure</b>	<b>22</b>
<b>3.12. Data Analysis and Statistical Test</b>	<b>23</b>
<b>3.13. Ethical Consideration</b>	<b>23</b>
<b>CHAPTER IV RESULT AND DISSCUSION</b>	<b>24</b>
<b>4.1. Result</b>	<b>24</b>
<b>4.2. Discussion</b>	<b>33</b>
<b>4.3. Study Limitation</b>	<b>38</b>
<b>CHAPTER V CONCLUSION AND SUGGESTION</b>	<b>39</b>
<b>5.1. Conclusion</b>	<b>39</b>
<b>5.2. Suggestion</b>	<b>39</b>
<b>REFERENCES</b>	<b>40</b>
<b>APPENDICES</b>	<b>44</b>

## LIST OF TABLES

Table 1 Study Originality	5
Table 2 Criteria Diagnosis of CKD	12
Table 3 Stages of CKD	12
Table 4 Baseline Characteristic	25
Table 5 Clinical Characteristic	26
Table 6 Areas and Major Domain that composed QoL	27
Table 7 QoL of the Study Subject by KDQOL SF-1.3	28
Table 8 Dependent and Independent Normality Test	29
Table 9 Confounding Factors Normality Test	30
Table 10 Correlation of Age and BMI to QoL using Pearson	31
Table 11 Correlation of Other Confounding to QoL using Spearman	31
Table 12 Correlation between Albumin and QoL	32

## LIST OF FIGURES

Figure 1 Kidney Anatomy	9
Figure 2 Principle of CAPD	13
Figure 3 Mechanism of CAPD	14

## **LIST OF APPENDICES**

Appendix A Correlation between Domains in QoL	44
Appendix B Correlation between Confounding Factors	45
Appendix C KDQOL-SF 1.3 Questionnaire	46
Appendix D Ethical Clearance	53

## LIST OF ABBREVIATIONS

<b>BCG</b>	Bromocresol Green
<b>BCP</b>	Bromocresol Purple
<b>BMI</b>	Body Mass Index
<b>CAPD</b>	Continuous Ambulatory Peritoneal Dialysis
<b>CCPD</b>	Cycler-assisted Peritoneal Dialysis
<b>CKD</b>	Chronic Kidney Disease
<b>CRP</b>	C-reactive Protein
<b>CT Scan</b>	Computerized Tomography Scan
<b>ESRD</b>	End Stage Renal Disease
<b>GFR</b>	Glomerular Filtrate Rate
<b>HD</b>	Hemodialysis
<b>IL-6</b>	Interleukin-6
<b>KDQOL-SF 1.3</b>	Kidney Disease Quality of Life Short Form-1.3
<b>MRI</b>	Magnetic Resonance Imaging
<b>QoL</b>	Quality of Life
<b>SF-36</b>	Short-Form survey 36
<b>WHO</b>	World Health Organization